RSS Feeds
Search

Companies

University of Arkansas for Medical Sciences

University of Arkansas for Medical Sciences
Medical School - Teaching Hospital - Research Institution

The company in detail

Profile

The University of Arkansas for Medical Sciences (UAMS) is the State’s only comprehensive academic health center, with five colleges, a graduate school, a new 540,000-square-foot hospital, six centers of excellence and a statewide network of regional centers. UAMS has 2,652 students and 733 medical residents. Its centers of excellence include the Winthrop P. Rockefeller Cancer Institute, the Jackson T. Stephens Spine & Neurosciences Institute, the Myeloma Institute for Research and Therapy, the Harvey & Bernice Jones Eye Institute, the Psychiatric Research Institute and the Donald W. Reynolds Institute on Aging. It is the state’s largest public employer with more than 10,000 employees, including nearly 1,150 physicians who provide medical care to patients at UAMS, Arkansas Children’s Hospital, the VA Medical Center and UAMS’ Area Health Education Centers throughout the state. Visit www.uams.edu or www.uamshealth.com

The largest-ever research grant earned by the UAMS has reached 17 faculty members dedicated to clinical and translational research. 

The UAMS Center for Clinical and Translational Research (CCTR) recently awarded more than $1.1 million to faculty dedicated to pursuing clinical and translational research in two separate programs. The CCTR Pilot Study program awarded more than $973,000 to 15 investigators across nine UAMS departments, while the KL2 Mentored Clinical Research Scholar program will provide nearly $200,000 of support for two winners. 

The UAMS CCTR is one of 46 medical research institutions working together as a national consortium to improve the way biomedical research is conducted across the country. The consortium, funded through Clinical and Translational Science Awards (CTSA), shares a common vision to reduce the time it takes for laboratory discoveries to become treatments for patients, and to engage communities in clinical research efforts. It also is fulfilling the critical need to train a new generation of clinical researchers. The CTSA program is led by the National Center for Research Resources (NCRR), part of National Institutes of Health (NIH).

UAMS BioVentures serves as the Technology Licensing Office, spin-out business accelerator, and the portal to all of the University's intellectual property and economic development programs. For more information, please visit www.uams.edu/bioventures or contact Michael G. Douglas, PhD mdouglas@uams.edu or Charlie Cook at (501) 686-6696 – e-mail CACook@uams.edu

Partnering strategy/interests

The University of Arkansas for Medical Sciences, through its Technology Licensing Office, UAMS BioVentures, is seeking global, commercial partners to out-license its' innovations for the purpose of taking its discoveries to the world's medical and healthcare market places.

Out-licensing

Acetaminophen-protein Adduct Dipstick: rapid, sensitive and specific diagnostic device for point-of-care determination of acetaminophen toxicity More
Customized laser skin treatment for superficial tumors, hair removal, Port-Wine Stain and other superficial vascular disorders. More
Novel agents capable of reaching remote cellular sites More
Tumor Biology - Therapeutic sequestering tumor cells growth and diagnostic as a tumor specific marker More
Diagnosis of functional heart disease and heart disease prognostication with emphasis on the multifractal alpha, the Levy flight analysis and the key discrete wavelet smoothing. More
An expression array diagnostic tool to predict survival in cancer patients, as well as, composition and methods to induce the predictive gene expression profile More
Application: Colposcopy - Foot-operated Focusing Device for Floor Stand Mounted Instruments More
A device and methods for the non-invasive manipulation and detection of target objects such as cells, pathogens, microparticles, and nanoparticles in vivo using an external magnetic field. More
An Endothelial lined Stent for Rapid Endothelialization and Preventing Restenosis More
Genetic cloning and sequencing of a novel IL-17 receptor-related gene More
Pneumatically measures uterine contractions during pregnancy, labor and delivery. More
Novel diagnostic and prognostic gene array classification system More
Diagnostic and/or Therapeutic Tool to modulate cell development and function More
Method of Measuring by Gas Dilution Residual Lung Volume in Infants More
Contrast agents for ultrasonic imaging, destruction of clots, ultrasound-induced permeability of blood vessels and other tissues, targeted drug delivery, or to enhance ultrasonic tissue ablation. More
precise and focused control of temperature mediated therapy and “triggering” deliverables in situ. More
Method of producing infectious papillomavirus in vitro and methods of making recombinant papillomavirus for vaccines More
Rapidly (less than 24 hours) diagnose MOTT infections in humans or animals More
In-home device to induce cycling motion in patients who have little or no motor control of their legs - increasing muscle mass and decreasing hyperreflexia More
Biomimic prenatal and postnatal maternal-to-infant transfer of clinical monosaccharides for improved neurologic development and immunologic functions More
Novel nonpalpable lesion detection procedure using hematoma - directed ultrasound and imaging. More
A Unique Fragment of Parathyroid Hormone Related Protein Predicts Breast Cancer Metastasis To Bone More
A Unique Fragment Of Parathyroid Hormone Related Protein Predicts Breast Cancer Metastasis To Bone. More
Prevents oral trauma to surgical or long term ventilated patients due to insertion of endotracheal tube; additionally this novel device is beneficial in endoscope labs for both bronchoscope and transesophageal echocardiogram (TEE) procedures. More
Surgical device, a catheter that enables a connection between the pancreatic duct and small bowel. More
Abdominal surgical closure device More
Thalidomide has been successfully used to successfully treat myeloma patients however, patients with high IL6R expression levels via gene expression profiling, do not benefit from the use of this drug. Therefore, the use of anti-IL6R therapies in combina More
drug delivery - a novel and effective method for the microencapsulation of small peptides that allows their use and controlled release over a time frame of several months. More
Gene array analysis and genetic testing uncovering a TP53 genetic deletion in multiple myeloma patients in combination with the use of risk-adapted therapy that incorporates thalidomide with bortezomib vastly improves patent outcomes. More
A device to position the arms of patietns during prolonged surgical procedures, to protect against nerve damage and also provide access to IV sites. More
a powerful Anti-Inflammatory pharmaceutical composition for use in established Allergic Contact Dermatitis More
Accurate placement of catheter needles More
Compositions and methods for targeted therapeutic release of encapsulated materials from multi functional liposomes at the site of a solid tumor or a diseased site using ionizing and non-ionizing radiation, a process called conformal Intensity Modulated R More
A multi-faceted invention that has identified novel compositions that may be useful for pharmacological, diagnostic and research development for more effective pain control. An in vitro enzymatic process that produces novel glucuronyl derivatives of canna More
Novel Surgical Clips for Vascular Bypass and Tissue Grafts for Vascular surgery, vascular grafts, sutureless anastomosis and bypass surgery More

Contact details

Mr. Christopher Fasel
Licensing Associate
UAMS BioVentures - TLO

Contact directly

Full contact list

Head office

University of Arkansas for Medical Sciences
UAMS BioVentures
Technology Licensing Office
4301 West Markham Street #831
Little Rock
Arkansas
72205-7199
Arkansas (USA)

Company figures

Formed: 1879
Number of employees: 9600

Related categories

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2012 Innovaro Europe Ltd Innovaro Corporation All rights reserved. Terms and Conditions | Contact us